MannKind Corp (MNKD) stock
MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30273% above fair value
$4.13−0.03 (-0.72%)
Close on Nov 13, 2026Market cap $1.33BP/E –Yield –
MannKind r&d expenses
Research and development expenses are spending on new products and technology.
MannKind's R&D Expenses for the twelve months ending Sep 30, 2026 was $77.18M, up 54.7% year over year. For fiscal 2025 it was $66.35M, up 44.6% from the year before. Over ten years it grew 8.4% a year on average. The highest annual figure on record is $156.33M in fiscal 2009.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.35M | +44.6% |
| FY2024 | Dec 31, 2024 | $45.89M | +46.7% |
| FY2023 | Dec 31, 2023 | $31.28M | +58.6% |
| FY2022 | Dec 31, 2022 | $19.72M | +60.2% |
| FY2021 | Dec 31, 2021 | $12.31M | +97.1% |
| FY2020 | Dec 31, 2020 | $6.25M | -9.4% |
| FY2019 | Dec 31, 2019 | $6.90M | -21.0% |
| FY2018 | Dec 31, 2018 | $8.74M | -38.1% |
| FY2017 | Dec 31, 2017 | $14.12M | -5.4% |
| FY2016 | Dec 31, 2016 | $14.92M | -49.7% |
| FY2015 | Dec 31, 2015 | $29.67M | -70.4% |
| FY2014 | Dec 31, 2014 | $100.24M | -8.6% |
| FY2013 | Dec 31, 2013 | $109.72M | +8.1% |
| FY2012 | Dec 31, 2012 | $101.52M | +1.6% |
| FY2011 | Dec 31, 2011 | $99.96M | -11.0% |
| FY2010 | Dec 31, 2010 | $112.28M | -28.2% |
| FY2009 | Dec 31, 2009 | $156.33M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $14.36M | +2.1% |
| Q2 FY2026 | Jun 30, 2026 | $18.00M | +31.6% |
| Q1 FY2026 | Mar 31, 2026 | $17.23M | +56.3% |
| Q4 FY2025 | Dec 31, 2025 | $27.59M | +147.7% |
| Q3 FY2025 | Sep 30, 2025 | $14.06M | +8.8% |
| Q2 FY2025 | Jun 30, 2025 | $13.68M | +15.7% |
| Q1 FY2025 | Mar 31, 2025 | $11.02M | +10.1% |
| Q4 FY2024 | Dec 31, 2024 | $11.14M | +20.6% |
| Q3 FY2024 | Sep 30, 2024 | $12.93M | +29.4% |
| Q2 FY2024 | Jun 30, 2024 | $11.82M | +83.1% |
| Q1 FY2024 | Mar 31, 2024 | $10.01M | +78.6% |
| Q4 FY2023 | Dec 31, 2023 | $9.24M | +29.1% |
| Q3 FY2023 | Sep 30, 2023 | $9.99M | +141.5% |
| Q2 FY2023 | Jun 30, 2023 | $6.45M | +31.9% |
| Q1 FY2023 | Mar 31, 2023 | $5.61M | +58.5% |
| Q4 FY2022 | Dec 31, 2022 | $7.16M | +84.1% |
| Q3 FY2022 | Sep 30, 2022 | $4.14M | +13.2% |
| Q2 FY2022 | Jun 30, 2022 | $4.89M | +110.1% |
| Q1 FY2022 | Mar 31, 2022 | $3.54M | +44.8% |
| Q4 FY2021 | Dec 31, 2021 | $3.89M | +151.5% |
| Q3 FY2021 | Sep 30, 2021 | $3.66M | +146.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.33M | +59.1% |
| Q1 FY2021 | Mar 31, 2021 | $2.44M | +39.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.55M | -23.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.48M | -6.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.46M | -10.3% |
| Q1 FY2020 | Mar 31, 2020 | $1.76M | +5.3% |
| Q4 FY2019 | Dec 31, 2019 | $2.02M | +86.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.58M | -22.7% |
| Q2 FY2019 | Jun 30, 2019 | $1.63M | -45.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.67M | -37.0% |
| Q4 FY2018 | Dec 31, 2018 | $1.08M | -69.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.04M | -53.2% |
| Q2 FY2018 | Jun 30, 2018 | $2.97M | -5.0% |
| Q1 FY2018 | Mar 31, 2018 | $2.64M | -15.5% |
| Q4 FY2017 | Dec 31, 2017 | $3.51M | +124.8% |
| Q3 FY2017 | Sep 30, 2017 | $4.36M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.12M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.13M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.56M | – |
See a number that looks wrong?